Targeted therapy of pancreatic cancer        LOU Wen-hui. General Surgery, Zhongshan Hospital, Fudan University, Shanghai 200032, China
Abstract    Targeted therapy is a main part of comprehensive therapy for pancreatic cancer. During the tumerogenesis and development of pancreatic cancer, lots of molecular could be the target of targeted therapy. Among dozens of molecular agents, only small molecular tyrosine kinase inhibitor erlotinib is proven to be effective against advanced pancreatic cancer in prospective randomized study. Unlike traditional cytotoxic agent, several aspects need to be adjusted in the conduction of targeted therapy research, such as heterogeneity of patients, proper endpoint and design.